aspartic acid has been researched along with Dementia, Vascular in 19 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Dementia, Vascular: An imprecise term referring to dementia associated with CEREBROVASCULAR DISORDERS, including CEREBRAL INFARCTION (single or multiple), and conditions associated with chronic BRAIN ISCHEMIA. Diffuse, cortical, and subcortical subtypes have been described. (From Gerontol Geriatr 1998 Feb;31(1):36-44)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The 2 patients with vascular dementia showed clinical improvement with marked increases in the NAA/Cre ratio and mini-mental score." | 2.69 | Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study. ( Hoshide, S; Kario, K; Matsuo, T; Shimada, K; Umeda, Y, 1999) |
| "Biochemical abnormalities in Alzheimer's Disease (AD), vascular dementia (VaD) and other primary degenerative dementias have been investigated using MRS." | 2.42 | 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. ( Jones, RS; Waldman, AD, 2004) |
| "Binswanger's disease is a form of subcortical ischemic vascular disease (SIVD-BD) with extensive white matter changes." | 1.51 | Biomarkers identify the Binswanger type of vascular cognitive impairment. ( Barry Erhardt, E; Caprihan, A; Pesko, JC; Prestopnik, J; Rosenberg, GA; Thompson, J, 2019) |
| "Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB." | 1.32 | 1H MR spectroscopy in common dementias. ( Boeve, BF; Edland, SD; Ferman, TJ; Ivnik, RJ; Jack, CR; Kantarci, K; Knopman, DS; O'Brien, PC; Petersen, RC; Smith, GE; Tang-Wai, DF; Tangalos, EG; Weigand, SD, 2004) |
| "Subcortical ischemic vascular dementia is associated with cortical hypometabolism and hypoperfusion, and this reduced cortical metabolism or blood flow can be detected with functional imaging such as positron emission tomography." | 1.31 | Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy. ( Amend, DL; Capizzano, AA; Chui, HC; Fein, G; Jagust, W; Maudsley, AA; Norman, D; Schuff, N; Segal, MR; Tanabe, JL; Weiner, MW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 1 |
| Zhang, Y | 1 |
| Liu, Y | 1 |
| Niu, X | 1 |
| Barry Erhardt, E | 1 |
| Pesko, JC | 1 |
| Prestopnik, J | 2 |
| Thompson, J | 2 |
| Caprihan, A | 1 |
| Rosenberg, GA | 3 |
| Gasparovic, C | 1 |
| Taheri, S | 1 |
| Huisa, B | 1 |
| Schrader, R | 1 |
| Adair, JC | 1 |
| Watanabe, T | 1 |
| Shiino, A | 1 |
| Akiguchi, I | 1 |
| Algin, O | 1 |
| Hakyemez, B | 1 |
| Parlak, M | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Waldman, AD | 2 |
| Rai, GS | 1 |
| Schuff, N | 2 |
| Capizzano, AA | 2 |
| Du, AT | 1 |
| Amend, DL | 2 |
| O'Neill, J | 1 |
| Norman, D | 4 |
| Jagust, WJ | 1 |
| Chui, HC | 2 |
| Kramer, JH | 1 |
| Reed, BR | 1 |
| Miller, BL | 1 |
| Yaffe, K | 1 |
| Weiner, MW | 4 |
| Marszał, E | 1 |
| Jamroz, E | 1 |
| Paprocka, J | 1 |
| Kluczewska, E | 1 |
| Sokół, M | 1 |
| Jones, RS | 1 |
| Kantarci, K | 1 |
| Petersen, RC | 1 |
| Boeve, BF | 1 |
| Knopman, DS | 1 |
| Tang-Wai, DF | 1 |
| O'Brien, PC | 1 |
| Weigand, SD | 1 |
| Edland, SD | 1 |
| Smith, GE | 1 |
| Ivnik, RJ | 1 |
| Ferman, TJ | 1 |
| Tangalos, EG | 1 |
| Jack, CR | 1 |
| Ross, AJ | 1 |
| Sachdev, PS | 1 |
| Wen, W | 1 |
| Valenzuela, MJ | 1 |
| Brodaty, H | 1 |
| Constans, JM | 2 |
| Meyerhoff, DJ | 2 |
| Gerson, J | 1 |
| MacKay, S | 2 |
| Fein, G | 3 |
| Kattapong, VJ | 1 |
| Brooks, WM | 1 |
| Wesley, MH | 1 |
| Kodituwakku, PW | 1 |
| Kario, K | 1 |
| Matsuo, T | 1 |
| Hoshide, S | 1 |
| Umeda, Y | 1 |
| Shimada, K | 1 |
| George, AE | 1 |
| Cha, S | 1 |
| Tanabe, JL | 1 |
| Maudsley, AA | 1 |
| Jagust, W | 1 |
| Segal, MR | 1 |
| De Stefano, N | 1 |
| Balestri, P | 1 |
| Dotti, MT | 1 |
| Grosso, S | 1 |
| Mortilla, M | 1 |
| Morgese, G | 1 |
| Federico, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Phase II, Randomized, Crossover, Single Blind, Safety Trial of DABIGATRAN Versus ASA for Preventing Ischaemic Brain Lesions in Patients Affected by CADASIL[NCT01361763] | Phase 2 | 50 participants (Anticipated) | Interventional | 2011-06-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
1 review available for aspartic acid and Dementia, Vascular
| Article | Year |
|---|---|
1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Alzheimer Disease; Aspartic Acid; Cerebral Cortex; Dementia, Vascular; Glutamic Acid; | 2004 |
4 trials available for aspartic acid and Dementia, Vascular
| Article | Year |
|---|---|
Absolute quantification in proton magnetic resonance spectroscopy is superior to relative ratio to discriminate Alzheimer's disease from Binswanger's disease.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differenti | 2008 |
Different patterns of N-acetylaspartate loss in subcortical ischemic vascular dementia and AD.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Dementia, Vascular; Diagnosis, Differential; Female; | 2003 |
1H MRS in stroke patients with and without cognitive impairment.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Biomarkers; Cerebral Cortex; Choline; Cognition Disorders; C | 2005 |
Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study.
Topics: Aged; Antithrombin III; Antithrombins; Arginine; Aspartic Acid; Biomarkers; Blood Coagulation; Brain | 1999 |
14 other studies available for aspartic acid and Dementia, Vascular
| Article | Year |
|---|---|
Naringenin Attenuates Cognitive Impairment in a Rat Model of Vascular Dementia by Inhibiting Hippocampal Oxidative Stress and Inflammatory Response and Promoting N-Methyl-D-Aspartate Receptor Signaling Pathway.
Topics: Animals; Anti-Inflammatory Agents; Aspartic Acid; Cognitive Dysfunction; Dementia, Vascular; Disease | 2022 |
Biomarkers identify the Binswanger type of vascular cognitive impairment.
Topics: Aged; Aspartic Acid; Biomarkers; Blood-Brain Barrier; Capillary Permeability; Dementia, Vascular; Fe | 2019 |
1H-MR spectroscopy metabolite levels correlate with executive function in vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Ischemia; Choline; Cogn | 2013 |
Proton MR spectroscopy and white matter hyperintensities in idiopathic normal pressure hydrocephalus and other dementias.
Topics: Adult; Aged; Aspartic Acid; Choline; Creatine; Dementia, Vascular; Diagnosis, Differential; Female; | 2010 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
Leukoencephalopathy with macrocephaly and mild clinical course.
Topics: Abnormalities, Multiple; Aspartic Acid; Brain; Child; Child, Preschool; Choline; Creatinine; Dementi | 2004 |
1H MR spectroscopy in common dementias.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Ch | 2004 |
H-1 MR spectroscopic imaging of white matter signal hyperintensities: Alzheimer disease and ischemic vascular dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Diseases; Brain Ischemia; Case-Control Studies; | 1995 |
Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain; Brain Ischem | 1996 |
Proton magnetic resonance spectroscopy of vascular- and Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Creatine; Dementia, Vascular; Diagnosis, Dif | 1996 |
Applying functional MR imaging to brain-behavioral research: can we do better than simple clinical measures?
Topics: Aspartic Acid; Brain; Brain Ischemia; Creatine; Dementia, Vascular; Humans; Magnetic Resonance Imagi | 2000 |
Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy.
Topics: Aged; Aspartic Acid; Brain Ischemia; Creatine; Dementia, Vascular; Female; Humans; Magnetic Resonanc | 2000 |
Severe metabolic abnormalities in the white matter of patients with vacuolating megalencephalic leukoencephalopathy with subcortical cysts. A proton MR spectroscopic imaging study.
Topics: Adolescent; Adult; Aspartic Acid; Creatine; Cysts; Dementia, Vascular; Disease Progression; Female; | 2001 |